Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.

@article{Borget2012CosteffectivenessOT,
  title={Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.},
  author={Isabelle Borget and Jacques Cadranel and Jean-Pierre Pignon and Elisabeth A Quoix and Bruno Coudert and V. Westeel and Eric Dansin and Jeannick Madelaine and Anne Madroszyk and Sylvie Friard and Catherine Daniel and Frank Morin and Christos Choua{\"i}d},
  journal={The European respiratory journal},
  year={2012},
  volume={39 1},
  pages={172-9}
}
Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not been evaluated. The objective of this study was to compare the incremental cost-effectiveness ratios of strategies for second-line erlotinib initiation in NSCLC: clinically guided initiation (nonsmoking females with adenocarcinoma received erlotinib; all other patients received docetaxel) and biologically… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS